TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04030442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immediate-release Oral Morphine Sulfate Tablets
Description: 0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-release Oral Morphine Sulfate Tablets
Description: 0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thermal and Pressure Nociceptive Sensitivity
Description: Primary outcome measures of pain threshold and tolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermal and Pressure Nociceptive Sensitivity
Description: Primary outcome measures of pain threshold and tolerance.
Study: NCT04236310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg (loading dose, 8mg/kg), infusion once every 3-week cycle for 5 cycles.
Study: NCT02851121

Intervention type: OTHER
Group type: OTHER
Intervention: Sensorial stimulations

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental protocols

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emotional protocols

Intervention type: OTHER
Group type: OTHER
Intervention: Protocol with a spatial dimension
Study: NCT02093780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alberta Anti-inflammatory diet
Description: Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Canada's Food Guide Diet
Description: Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
Study: NCT02332057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac plus lidocaine
Description: The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
Study: NCT02019472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg
Description: SC injections
Study: NCT02765828

Intervention type: OTHER
Intervention: Observational study
Description: The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements

Intervention type: OTHER
Intervention: Observational study
Description: The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements

Intervention type: OTHER
Intervention: Observational study
Description: The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
Study: NCT02019472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg
Description: SC injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections
Study: NCT02361190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 1ml aqueous saline spray
Study: NCT04504929

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tape
Description: Use sham type on the pitching shoulder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: Use dynamic type on the pitching shoulder for supporting internal rotation
Study: NCT02247570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
Study: NCT02479828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: 40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03432299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA for PTMC
Description: Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
Study: NCT04261478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery stenting
Description: The type of stent should be one commonly used for ICA stenting. Balloon angioplasty before and/or after stent placement will be allowed as required. Stenting should be performed after intracranial thrombectomy unless specific technical circumstances suggest that access to the intracranial circulation requires anterograde stenting. Embolic protection devices should not be used routinely during ICA stent placement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: The following antiplatelet regimen should be used: For patients having received IV thrombolysis, immediate post-procedural oral or intrarectal single antiplatelet agents, (Aspirin 325mg PO or 650mg PR). A second agent (usually Clopidogrel 300mg PO) is added after follow-up brain imaging at 12-24 hours confirms absence of significant ICH. For patients having not been treated with IV thrombolysis, dual antiplatelet therapy (Aspirin 325mg PO or 650mg PR and Clopidogrel 300-600mg PO) is given immediately post-procedure. Routine use of GPIIb/IIIa inhibitors, periprocedural IV Heparin is discouraged.
Study: NCT03047382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AKI Care Bundle
Description: Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
Study: NCT00950833

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: 1 or 2 intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: 1 or 2 intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: 1 or 2 intramuscular injections
Study: NCT01706198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate + vilanterol
Description: once daily via a Novel Dry Powder Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled corticosteroid with or without a long acting beta2-agonist
Description: ICS alone or in combination with a long acting bronchodilator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroid with or without a long acting beta2-agonist
Description: ICS alone or in combination with a long acting bronchodilator
Study: NCT01396759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bubble continuous positive airway pressure
Description: All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Humidified high flow air / O2 mix at 2 l/kg/min
Description: Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min
Description: Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (\>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
Study: NCT04295460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomize
Description: Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomize
Description: Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment
Study: NCT02514590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom SCS System
Description: This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 Hz therapy.
Study: NCT01166971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSTOR +3
Description: Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis MF
Description: Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
Study: NCT03400371

Intervention type: OTHER
Intervention: Blood draw
Description: Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.

Intervention type: OTHER
Intervention: Existing samples
Description: Control DNA samples will be used that have been previously acquired in other studies.
Study: NCT01494220

Intervention type: DEVICE
Intervention: Bispectral index monitoring (BIS)
Description: BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
Study: NCT01907659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Release of test results
Description: Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
Study: NCT03208348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot Virtual Reality
Description: Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
Study: NCT01234259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Freeze (MP2 V2 System
Description: Facial wrinkles and temporary cellulite and circumference reduction treatments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Venus Freeze (MP2 V2 System
Description: Facial wrinkles and temporary cellulite and circumference reduction treatments
Study: NCT04104711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits, health education
Study: NCT04221581

Intervention type: DEVICE
Intervention: Knee prosthesis - FHK ASYMETRIQUE total knee prosthesis
Description: FHK ASYMETRIQUE prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
Study: NCT02151461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Metformin
Description: 1100 mg L Leucine in combination with 125 mg of Metformin BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Metformin
Description: 1100 mg of Leucine in combination with 250 mg Metformin BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Metformin
Description: 1100 mg of Leucine in combination with 500 mg Metformin BID
Study: NCT01456052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Etiprate
Description: 500 mg telotristat etiprate (LX1606) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Etiprate
Description: 500 mg telotristat etiprate (LX1606) administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally.
Study: NCT03716102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with implantation with DES
Description: PCI with implantation with DES
Study: NCT03343106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT plus ERP
Description: 16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERP alone
Description: 16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
Study: NCT01531348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSC
Description: Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
Study: NCT01606137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
Study: NCT00911859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab11 mg/kg
Description: Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab 8.3 mg/kg or 11 mg/kg
Description: Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade (bortezomib)
Description: Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will take prednisone 60 mg/m2 orally according to the package insert.
Study: NCT03806894

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of platelet aggregation
Description: Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantification of platelet aggregation
Description: Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
Study: NCT01768078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Betamethasone + antibiotics

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravitreal injection of antibiotics
Study: NCT03553277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transfluthrin
Description: passive emanator with formulated transfluthrin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: passive emanator with formulated inert ingredients
Study: NCT00480220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global care and support program
Study: NCT01798485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 75 mg/m\^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib, 150 mg/m\^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
Study: NCT03522740

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid for Renal Therapy
Description: DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
Study: NCT04127591

Intervention type: OTHER
Intervention: exosome
Description: Collect exosomes in peripheral blood of patients and extract miRNAs from them.

Intervention type: OTHER
Intervention: exosome
Description: Collect exosomes in peripheral blood of patients and extract miRNAs from them.
Study: NCT01663714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.
Description: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
Study: NCT01612156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine gel
Description: 2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water based lubricant
Description: Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
Study: NCT04523493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab combined with Lenvatinib
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo combined with Lenvatinib
Description: Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.